View Document Preview and Link Document Date: 2012-06-04 17:17:09 Open Document File Size: 3,67 MB Share Result on Facebook
City Effectiveness Conclusion / / Company AEs / Oregon Drug Effectiveness Review / / Continent North America / / Country United States / / Currency USD / / Event Product Issues / Product Recall / / Facility DoD Pharmacoeconomic Center / Fort Sam Houston / / IndustryTerm ophthalmic solution / alcaftadine ophthalmic solution / fixed-dose combination product / / MedicalCondition nonfatal stroke / acute coronary syndromes / prior stent thrombosis / ischemic stroke / nausea / non-fatal myocardial infarction / transient ischemic attack / coronary syndrome / oral non-insulin diabetes / neutropenia and aplastic anemia / constipation / cerebral infarction / dyspnea / stroke / recurrent stroke / allergic conjunctivitis / vomiting / serotonin syndrome / pain / diabetes mellitus / Pancreatitis / peripheral artery disease / In stroke / Acute renal failure / / MedicalTreatment bypass / / Organization P&T Committee / DoD P&T Committee / MRS Aggrenox / DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS / U.S. FOOD AND DRUG ADMINISTRATION / DoD Pharmacoeconomic Center / Department of Defense / / Person Jonathon Woodson / / Position rector / Director / Major / / Product Avinza / B. Narcotic Analgesics-Tapentadol Extended Release Tablets / Janumet / morphine sulfate / simvastatin / Persantine / Pletal / Trental / Kadian / Opana ER / ibuprofen / Patanol / pentoxifylline / cilostazol / clopidogrel / dipyridamole / Plavix / fentanyl / Aggrenox / Januvia / Oxycontin / Ticlid / / ProvinceOrState Texas / Newfoundland / Michigan / / PublishedMedium The D ERP review / / SocialTag 
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS February 2012 I. CONVENING The Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee convened at 0800 hours on February 16 and 1